Editas Medicine (EDIT) Return on Equity (2016 - 2025)

Editas Medicine (EDIT) has 10 years of Return on Equity data on file, last reported at 0.07% in Q4 2025.

• Quarterly Return on Equity fell 6.0% year-over-year to 0.07% in Q4 2025, while the trailing twelve-month figure through Dec 2025 was 0.07% (down 6.0% YoY) and the FY2024 annual result came in at 0.01%, down 1.0% from the prior year.
• Return on Equity climbed to 0.07% in Q4 2025 per EDIT's latest filing, from 0.12% in the prior quarter.
• Across five years, Return on Equity topped out at 0.0% in Q2 2021 and bottomed at 0.12% in Q3 2025.
• The 5-year median for Return on Equity is 0.01% (2022), against an average of 0.02%.
• The widest annual swing landed in 2021, when Return on Equity changed 0 bps; it then slipped 11 bps in 2025.
• Tracing EDIT's Return on Equity over 5 years: stood at 0.0% in 2021, then slumped by 68 bps to 0.01% in 2022, then rose by 25 bps to 0.0% in 2023, then tumbled by 258 bps to 0.02% in 2024, then slumped by 388 bps to 0.07% in 2025.
• Per Business Quant, the three latest EDIT Return on Equity figures stand at 0.07% (Q4 2025), 0.12% (Q3 2025), and 0.06% (Q2 2025).

Peer Comparison